Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd + Rilvegostomig in High-risk Muscle Invasive Urothelial Carcinoma
NCT07720284Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- Sep 2030
- Countries
- 16
01
Overview
A Phase 3 trial of datopotamab deruxtecan, rilvegostomig in urothelial carcinoma (UC), sponsored by AstraZeneca. Started Jul 2026; status: recruiting.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07720284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720284.